Trial Profile
A Phase IIIb, Multicentre, Open-label Study of Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome and/or BCR-ABL Positive CML in Chronic Phase - ENEST1st
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ENEST1st; MACS1252
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jan 2017 Results of a sub-study (n=52) assessing immune-modulating potential of nilotinib, published in the Journal of Clinical Oncology
- 06 Dec 2016 Results of sub-study (n=52) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 07 Jun 2016 Results (analyzing quantification of BCR-ABL and molecular responses in patients who had undergone treatment in ENEST1st trial) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.